NCT04136028View on ClinicalTrials.gov

IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 25, 2015

Primary Completion Date

January 16, 2019

Study Completion Date

January 31, 2020

Conditions
Chronic Granulomatous Disease
Interventions
DRUG

Kineret

Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time

Trial Locations (1)

117198

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER

NCT04136028 - IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease | Biotech Hunter | Biotech Hunter